Offer Description
The aim of this project is to develop and validate TRN-228 (cebranopadol), a novel MOP/NOP dual receptor agonist, as a safer and more effective treatment for opioid use disorder (OUD). Unlike current OUD therapies that target only MOP receptors, cebranopadol's dual mechanism has shown promise in reducing abuse potential, dependence, and respiratory depression. The project includes nonclinical and clinical studies aimed at demonstrating the therapeutic potential and safety profile of TRN-228 compared to current standard treatments. The selected candidate will be instrumental in coordinating and implementing experimental activities, data analysis, and reporting, as UNICAM's contribution to the consortium
Where to apply Website
Requirements
Additional Information
Eligibility criteria
Eligible destination country/ies for fellows:
- Italy
Eligibility of fellows: country/ies of residence:
- AFRICA
- EUROPE
- OCEANIA
- NORTH AMERICA
- SOUTH AMERICA
- ASIA
Eligibility of fellows: nationality/ies:
- AFRICA
- EUROPE
- OCEANIA
- NORTH AMERICA
- SOUTH AMERICA
- ASIA
Website for additional job details
Work Location(s)
Number of offers available 1 Company/Institute UNICAM Country Italy Geofield
Contact City
Camerino Website
STATUS: EXPIRED
Share this page